{"top_spans": [[0, 0], [1, 1], [2, 2], [2, 3], [11, 11], [16, 19], [16, 21], [19, 19], [19, 21], [21, 21], [24, 24], [24, 29], [25, 29], [33, 33], [43, 43], [54, 54], [56, 64], [56, 65], [65, 65], [66, 66], [66, 67], [67, 67], [67, 70], [67, 71], [68, 68], [68, 70], [68, 71], [71, 71], [72, 81], [77, 77], [79, 79], [80, 81]], "predicted_antecedents": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "document": ["gilead", "announces", "96-week", "results", "from", "phase", "3", "study", "of", "biktarvy", "\u00ae", "bictegravir", "emtricitabine", "tenofovir", "alafenamide", "for", "the", "treatment", "of", "hiv-1", "in", "adults", "new", "to", "hiv", "therapy", "foster", "city", "calif", "business", "wire", "-oct", "30", "2018-gilead", "sciences", "inc", "nasdaq", "university", "of", "hamburg", "gilead", "sciences", "inc", "96-week", "fanconi", "syndrome", "lactic", "acidosis", "scotland", "hiv", "infection", "gilead", "sciences", "ftc", "glasgow", "crcl", "tenofovir", "hiv", "hans", "-", "j\u00fcrgen", "stellbrink", "emtricitabine", "germany", "hiv", "glasgow", "united", "states", "gilead", "public", "affairs", "gilead", "gilead", "quarterly", "biktarvy", "foster", "city", "california", "hbv", "immune", "reconstitution", "syndrome"], "clusters": []}